As global markets react to the recent Fed rate cut, Hong Kong's Hang Seng Index has seen a significant uptick, gaining 5.12% in a holiday-shortened week. This positive momentum provides an opportune backdrop for exploring high growth tech stocks in Hong Kong for September 2024. In light of these market conditions, identifying good stocks involves focusing on companies with strong fundamentals and innovative capabilities that can capitalize on the current economic environment.

Top 10 High Growth Tech Companies In Hong Kong

Click here to see the full list of 45 stocks from our SEHK High Growth Tech and AI Stocks screener.

Underneath we present a selection of stocks filtered out by our screen.

Mobvista

Simply Wall St Growth Rating: ★★★★☆☆

Overview: Mobvista Inc., along with its subsidiaries, provides advertising and marketing technology services essential for developing the mobile internet ecosystem globally, with a market cap of HK$2.09 billion.

Operations: The company operates primarily through two segments: Marketing Technology Business and Advertising Technology Services, generating revenues of $16.98 million and $1.17 billion respectively. The focus is on providing technology solutions that support the mobile internet ecosystem globally.

Mobvista, a player in Hong Kong's tech scene, reported a slight dip in net income to $9.27 million from $10.16 million year-over-year despite boosting sales by 26% to $638.29 million for the first half of 2024. This performance underscores its ability to scale revenue amidst challenging market conditions, though profit margins face pressures. Notably, Mobvista's commitment to innovation is evident from its R&D investments which align with its revenue growth trajectory at 15.3% annually, promising enhancements in mobile advertising technologies that could spur future growth phases especially as it outpaces the Hong Kong market average growth rate of 7.3%. With earnings expected to surge by 31.1% per year, significantly outstripping the local market’s forecasted 11.8%, Mobvista is poised for robust future earnings potential if it continues leveraging technological advancements and maintaining cost efficiencies.

• Unlock comprehensive insights into our analysis of Mobvista stock in this health report.

• Gain insights into Mobvista's historical performance by reviewing our past performance report.

Tencent Holdings

Simply Wall St Growth Rating: ★★★★☆☆

Overview: Tencent Holdings Limited, an investment holding company, provides a range of services including online advertising, fintech, and business solutions both in China and internationally with a market cap of HK$3.70 trillion.

Operations: Tencent Holdings Limited generates revenue primarily through value-added services (CN¥302.28 billion), online advertising (CN¥111.89 billion), and fintech and business services (CN¥209.17 billion).

Tencent Holdings has demonstrated a robust financial performance with its recent earnings report showing a substantial increase in net income to CNY 47.63 billion for Q2 2024, up from CNY 26.17 billion in the same period last year, reflecting an impressive growth trajectory. This surge is supported by a solid revenue hike to CNY 161.12 billion, marking an annual increase of 8%. The company's commitment to innovation is clearly reflected in its R&D spending trends which are closely aligned with revenue growth, ensuring continued advancements in its core segments like digital content and online gaming. Notably, Tencent's strategic presentations at the CITIC CLSA Investor's Forum underscored these points, potentially setting the stage for sustained future growth amidst competitive pressures and market dynamics.

• Get an in-depth perspective on Tencent Holdings' performance by reading our health report here.

• Learn about Tencent Holdings' historical performance.

RemeGen

Simply Wall St Growth Rating: ★★★★★☆

Overview: RemeGen Co., Ltd. is a biopharmaceutical company focused on discovering, developing, and commercializing biologics for autoimmune, oncology, and ophthalmic diseases in Mainland China and the United States, with a market cap of HK$11.52 billion.

Operations: RemeGen generates revenue primarily through biopharmaceutical research, services, production, and sales, amounting to CN¥1.40 billion. The company operates in Mainland China and the United States, focusing on treatments for autoimmune, oncology, and ophthalmic diseases with unmet medical needs.

RemeGen's recent financials reveal a challenging landscape with a net loss widening to CNY 780.46 million from CNY 703.36 million year-over-year, despite sales growth from CNY 419.07 million to CNY 739.66 million in the first half of 2024. This juxtaposition highlights the firm's aggressive investment in R&D, crucial for its innovative drug telitacicept, which has shown promise in international clinical trials for treating myasthenia gravis—a market poised to expand significantly by 2025. The company's strategic focus on novel therapies is evident as it navigates through regulatory successes and broadens its treatment portfolio, aiming to meet urgent global medical needs while grappling with financial volatility.

• Click to explore a detailed breakdown of our findings in RemeGen's health report.

• Explore historical data to track RemeGen's performance over time in our Past section.

Seize The Opportunity

• Explore the 45 names from our SEHK High Growth Tech and AI Stocks screener here.

• Invested in any of these stocks? Simplify your portfolio management with Simply Wall St and stay ahead with our alerts for any critical updates on your stocks.

• Elevate your portfolio with Simply Wall St, the ultimate app for investors seeking global market coverage.

Curious About Other Options?

• Explore high-performing small cap companies that haven't yet garnered significant analyst attention.

• Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.

• Find companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include SEHK:1860 SEHK:700 and SEHK:9995.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com